Gemina Laboratories Ltd. (OTCPK: GLAB.F)
Health Care · Biotechnology · CA
$—
— today · — 1Y
Gemina Laboratories Ltd. (OTCPK: GLAB.F) operates in the Biotechnology industry within the Health Care sector.
trading between 0.04 and 0.92.
Tweenvest scores Gemina Laboratories Ltd. across four factors: quality 18/100. Its strongest factor is quality.
GLAB.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $7.76K
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.92
- 52-week low
- $0.04
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 6
- Next earnings
- —
About Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
- ISIN
- CA3686501071
- Founded
- 2017
- Listed since
- Aug 12, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.